By Jamie Lennox ( October 2, 2025, 4:21 PM BST) -- A European appeals panel has refused to rekindle Neurim's insomnia drug patent, ruling in a decision released Thursday that officials did not misstep by making passing comments on the patent's validity without hearing the Israeli company's opinion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.